Picture of Nick Beckett

Nick Beckett

Managing Partner
Beijing Office, Global Co-Head of Lifesciences

CMS China
Beijing Representative Office
Room 1909, China Youth Plaza
No. 19 Dongsanhuan North Road
Chaoyang District, Beijing 100026
China
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English, French
Dispute Resolution

Nick Beckett is the Managing Partner of the Beijing Office, Global Co-Head of Lifesciences and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region. 

He has extensive experience in dispute resolution, particularly intellectual property and in the Lifesciences and TMC sectors.  Nick’s practice has involved coordinating complex multi-jurisdictional matters in the areas of commercial and corporate disputes, parallel trade, anti-counterfeiting and trade mark and patent litigation.

more less

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • One of the world’s leading information technology services companies and successfully defending it in China against a top Chinese state-owned enterprise and its subsidiaries in respect of a management consultancy project and an ERP project that our client implemented for them under a global strategic framework agreement.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions, including China.
  • A leading global bed specialist on the highly sensitive and important employment termination of its former management team in China, including its Managing Director and two senior sales leaders based on unsatisfactory performance and serious wrongdoings.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • Asahi Medical in patent litigation in the UK Patents Court and Court of Appeal for a large Japanese medical device company in connection with their blood filtration technology. This also entailed coordinating concurrent litigation across Europe and liaising with the client's Japanese and European patent attorneys.
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • Takeda on successfully opposing the grant of a competitor’s (Bethesda Pharmaceuticals Inc) European patent at the Opposition Division of the European Patent Office.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
  • Sports World International in numerous trade mark litigation matters relating to its own and licensed brands including Kangol, Diadora, Puma and Lonsdale.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

Listed on the ‘BAC/BIAC Panel of Arbitrators’

more less
Intellectual Property

Nick Beckett is the Managing Partner of the Beijing Office, Global Co-Head of Lifesciences and Head of Asia-Pacific IP. Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region.

Nick has extensive experience in advising on all aspects of intellectual property and commercial matters affecting a wide range of international clients, particularly in the Lifesciences and TMC sectors.  Nick’s practice spans both contentious and non-contentious issues and has involved coordinating complex multi-jurisdictional matters in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, due diligence and trade mark and patent opinions. 

more less

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • A European automotive manufacturer in its IP licensing and actions to protect its portfolio from alleged infringement in many jurisdictions by several companies, including China.
  • Erbe in the first ever UK patent litigation to deal separately with the issues of infringement and validity coordinating with equivalent litigation in Germany, the US and before the EPO.
  • A world leading IT network company on the coordination of enforcement activity against a Chinese trademark infringer.
  • A leading international agrochemical company for the client's Crop Protection Business on patent infringement, anti-counterfeiting, customs and regulatory dispute work, including coordinating with other CMS offices and bringing together a network to service the client's needs.
  • An art tools manufacturer on the strategic restructuring of its trademark portfolio in China and the implementation of further agreements to bolster the value of its rights.
  • A world-leading supplier of edible coatings to the pharmaceuticals industry in connection with a patent infringement matter spanning a number of jurisdictions. This involved coordinating patent litigation and patent prosecution, as well as advising the client on general commercial strategy.
  • A Hong Kong based biotechnology company on a freedom to operate (FTO) search on a number of its core products across Asia-Pacific.
  • BudejovickyMetanskyPivovar in trade mark litigation with Anheuser- Busch relating to use of the term BUDWEISER.
  • A major US pharmaceutical company in disputes with numerous parallel traders.
  • Quinn Group in connection with a branding dispute regarding the rebranding of the Belfry Hotel as part of the De Vere hotel chain.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

Listed on the ‘BAC/BIAC Panel of Arbitrators’

more less
Lifesciences

Nick Beckett is the Managing Partner of the Beijing Office, Global Co-Head of Lifesciences and Head of Asia-Pacific IP.  Nick manages a team of dedicated sector specialists covering Lifesciences, Energy, TMC and Financial Institutions across the Asia-Pacific region.

Nick has extensive experience in advising on all aspects of intellectual property and commercial matters affecting a wide range of international clients, particularly in the Lifesciences sector.  His practice spans both contentious and non-contentious issues and has involved coordinating complex multi-jurisdictional matters in the areas of commercial and corporate transactions and disputes, parallel trade, anti-counterfeiting, due diligence and trade mark and patent opinions. 

more less

Heavyweight IP, parallel trade and patent litigation capability for an impressive roster of clients.

Legal 500

Nick is recommended as a prominent practitioner in his field in the Global Law Experts 2015 for China, PLC Lifesciences Handbook, Super Lawyers London and the Guide to the World’s Leading Trade Mark Law Practitioners.

Relevant experience

  • Takeda Pharmaceutical Company Limited on its €9.6 billion (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S.
  • A Japanese pharmaceutical company in a very significant ICC arbitration, with damages of up to $1 billion, concerning a dispute under a worldwide patent licence agreement in the pharmaceutical sector as a result of the wrongful withdrawal of a licensed pharmaceutical product from the market without consent.
  • A global pharmaceutical company on its market entry into China including obtaining relevant licence and setting up a compliance program, establishing its branch company in China and preparing and submitting the legal documents for the registration with the local authorities.
  • A world leading gas supplier on its joint medical institution project in China in cooperation with its domestic partner from various perspectives (corporate, compliance, regulatory and commercial).
  • A leading global pharmaceutical company in a high profile dispute concerning a blockbuster pharmaceutical product. The dispute entailed coordinating litigation in Japan and the UK and jurisdictional issues. Complex pharmaceutical litigation, as well as complicated questions of contract law arose.
  • One of the leading traditional Chinese medicine (TCM) companies in China in its management control dispute relating to a joint venture in The Netherlands.
  • Eli Lilly in a leading pharmaceutical parallel trade repackaging case before the CJEU.
  • A global leading medical device company on a strategically important investigation into a compliance breach within their distribution channels in Indonesia and South-East Asia.
  • A Japanese pharmaceutical company on conducting IP due diligence in respect of 2 anti-depressant compounds the subject of a successful world-wide collaboration agreement.
  • A Tianjin-based biotechnology company specialising in novel HIV biologics on international pre-clinical through to Phase III clinical trial development.  Identifying opportunities and facilitating introductions to potential R&D partners in Europe and North America.  Advising on potential entry into Western pharmaceutical markets and the feasibility of deal structures, including the licensing of intellectual property and establishing joint ventures.
more less

Education

2005 - Advocacy Diploma, The College of Law, London

2000 - Intellectual Property Diploma, Bristol University, Bristol

1996 - LPC Distinction, The College of Law, London

1996 - Professional Skills Course, BPP, London

1995 - CPE Distinction, Manchester Metropolitan University, Manchester

1994 - BSc Hons Psychology 1st, University of Manchester, Manchester

more less

Memberships

Honorary Lecturer - China Pharmaceutical University, Nanjing, China

Lecturer - Peking University, China

Lecturer - University of International Business and Economics (UIBE) 

Lecturer - China-EU School of Law, China University of Political Science and Law

Listed on the ‘BAC/BIAC Panel of Arbitrators’

more less

Feed

Show only
15/10/2009
CMS European Pat­ents Re­view
31/10/2017
China Lifes­ci­ences Monthly Up­date - Oc­to­ber 2017
New rules on drug clin­ic­al tri­al in­sti­tu­tions draf­ted, 26 Oc­to­ber China Food and Drug Ad­min­is­tra­tion (“CF­DA”) is­sued Ad­min­is­trat­ive Pro­vi­sions on Clin­ic­al Drug Tri­al In­sti­tu­tions (Draft for com­ment) (the “Draft”) on 26 Oc­to­ber 2017.
20/09/2017
China Monthly TMT Up­date – Septem­ber 2017
The CAC pub­lishes two new reg­u­la­tions gov­ern­ing BBS and on­line com­ment ser­vices The Cy­ber­space Ad­min­is­tra­tion of China (“CAC”) pub­lished the Ad­min­is­trat­ive Pro­vi­sions on On­line Bul­let­in Board Sys­tem (“BBS”) and Com­munity Ser­vices and the Ad­min­is­trat­ive Pro­vi­sions.
11/09/2017
Draft cy­ber­se­cur­ity law stand­ards are pub­lished to guide the prac­tice
Dur­ing the last week of Au­gust 2017, the Na­tion­al In­form­a­tion Se­cur­ity Stand­ard­iz­a­tion Tech­nic­al Com­mit­tee (the so-called TC260) pub­lished a series of draft tech­nic­al stand­ards to so­li­cit pub­lic opin­ions.
15 Nov 17
We­bin­ar: Cy­ber­se­cur­ity in Asia Pa­cific: What you need...
11/09/2017
Chinese “Or­ange Book” – open for pub­lic com­ments
Fol­low­ing the pub­lic­a­tion of “An­nounce­ment on Rel­ev­ant Mat­ters con­cern­ing the Eval­u­ation of Con­sist­ency of the Qual­ity and Ef­fic­acy of Gen­er­ic Drugs”, the Cen­ter for Drug Eval­u­ation (“CDE”)  of the China Food and Drug Ad­min­is­tra­tion is­sued the Cata­logue of.
07 Nov 17
CMS Glob­al Lifes­ci­ences For­um 2017
Dy­nam­ic Mar­kets and Vir­tu­al Risks
30/08/2017
The leg­al and reg­u­lat­ory chal­lenges of get­ting a bi­osim­il­ar product...
After a pharma view on bi­osim­il­ars was provided in the pre­vi­ous Ex­pert View column, a leg­al per­spect­ive is provided by Nick Beck­ett, man­aging part­ner at CMS Beijing and glob­al co-head of the firm­'s lifes­ci­ences sec­tor group.
08 Oct 17
IBA An­nu­al Meet­ing 2017 Sydney
Our CMS del­eg­ates
28/08/2017
China Monthly TMT Up­date – Au­gust 2017 
China pub­lishes the de­vel­op­ment plan for AIs  The State Coun­cil pub­lished the De­vel­op­ment Plan for the New Gen­er­a­tion of Ar­ti­fi­cial In­tel­li­gence (the “Plan”) on 20 Ju­ly 2017, which sets out the stra­tegic tar­gets for the de­vel­op­ment of ar­ti­fi­cial in­tel­li­gence.
25/08/2017
China launches the first in­ter­net court in Hang­zhou
The world’s first court spe­cial­ising in hand­ling in­ter­net-re­lated cases opened last week in China in the city of Hang­zhou, Zheji­ang Province, the cent­ral hub of e-com­merce. The Hang­zhou In­ter­net Court (the “Court”) will tri­al in­ter­net re­lated dis­putes on the.
08/08/2017
MOF­COM amends the In­ter­im Ad­min­is­trat­ive Meas­ures for the Re­cord-fil­ing...
On 30 Ju­ly 2017, the Min­istry of Com­merce (the “MOF­COM”) an­nounced a de­cision to amend (the "Amend­ment De­cision”), the In­ter­im Ad­min­is­trat­ive Meas­ures for the Re­cord-fil­ing of the In­cor­por­a­tion and Change of For­eign-in­ves­ted En­ter­prises (the “Meas­ures”).
31/07/2017
China Lifes­ci­ences Monthly Up­date – Ju­ly 2017
Prin­ciples for Stand­ard­ising Names of Foods for Spe­cial Med­ic­al Pur­poses, 21 Ju­ly The China Food and Drug Ad­min­is­tra­tion ("CF­DA") is­sued the Opin­ions on the Prin­ciples for Stand­ard­ising Names of Foods for Spe­cial Med­ic­al Pur­poses (for Tri­al Im­ple­ment­a­tion).
24/07/2017
China Monthly TMT Up­date – Ju­ly 2017
Draft guideline for the es­tab­lish­ment of na­tion­al in­dus­tri­al sys­tem of telemat­ics is pub­lished The Min­istry of In­dustry and In­form­a­tion Tech­no­logy and the Stand­ard­isa­tion Ad­min­is­tra­tion of China have jointly pub­lished the Draft Guideline for the Es­tab­lish­ment.
21/07/2017
China launches spe­cif­ic Pro­gram against fraud­u­lent and false ad­vert­ising...
Re­cently, the Food Safety Of­fice of the State Coun­cil (the “Of­fice”) and nine oth­er de­part­ments jointly is­sued the No­tice on the Pro­gram of Over­haul­ing Fraud­u­lent and False Ad­vert­ising of Food and Di­et­ary Sup­ple­ments (the “No­tice”).